Literature DB >> 33664166

Synthesis and characterization of enantiopure planar-chiral phosphorus-linked diferrocenes.

Philipp Honegger1, Alexander Roller2, Michael Widhalm3.   

Abstract

In the course of an ongoing synthetic project on cyclic diferrocenylphosphines, we obtained a groupn> of planar-chiral diferrocenyl compounds useful as precursors for subsequent cyclization. Here we report the crystal structures of two symmetric compounds [(FcA)2(Ph)P], one of which contains four stereogenic centres (two C chiral and two planar chiral centres), i.e. 1,1'-(phenylphosphanediyl)bis{(2Sp)-2-[(1R)-1-(acetyloxy)ethyl]ferrocene}, [Fe2(C5H5)2(C24H25O4P)], and the other phosphine sulfide is a purely planar-chiral compound (two planar chiral centres), i.e. bis[(2Sp)--2-ethenylferrocen-1-yl]phenylphosphane sulfide, [Fe2(C5H5)2(C20H17PS)]. Owing to the stereocentres present, reactions performed on [(FcA)2(Ph)P]-type compounds strongly favour one ferrocene unit over the other due to diastereoselectivity. Furthermore, we present four related structures where the ferrocene units are not identical [(FcA)(FcB)(Ph)P]. These are {(2Sp)-2-[(1R)-1-(acetyloxy)ethyl]ferrocen-1-yl}[(2Sp)-2-ethenylferrocen-1-yl]phenyl-(S)-phosphine sulfide, [Fe2(C5H5)2(C22H21O2PS)], [(2Sp)-2-ethenylferrocen-1-yl]{(2Sp)-2-[(1R)-1-hydroxyethyl]ferrocen-1-yl}phenyl-(S)-phosphine sulfide, [Fe2(C5H5)2(C20H19OPS)], {(2Sp)-2-[(1R)-1-(acetyloxy)ethyl]ferrocen-1-yl}{(2Sp)-2-[(1R)-1-hydroxyethyl]ferrocen-1-yl}phenyl-(R)-phosphine sulfide, [Fe2(C5H5)2(C22H23O3PS)], and {(2Sp)-2-[(1R)-1-benzylamino)ethyl]ferrocen-1-yl}[(2Sp)-2-ethenylferrocen-1-yl]phenyl-(S)-phosphine sulfide, [Fe2(C5H5)2(C27H26NPS)]. All of the structures are accessible in one step from known precursors. open access.

Entities:  

Keywords:  chirality; crystal structure; ferrocene; metal organic; phosphine sulfide; planar chirality; three-dimensional structure

Year:  2021        PMID: 33664166      PMCID: PMC7941264          DOI: 10.1107/S2053229621001996

Source DB:  PubMed          Journal:  Acta Crystallogr C Struct Chem        ISSN: 2053-2296            Impact factor:   1.172


  9 in total

1.  Novel chiral biferrocene ligands for palladium-catalyzed allylic substitution reactions.

Authors:  Li Xiao; Walter Weissensteiner; Kurt Mereiter; Michael Widhalm
Journal:  J Org Chem       Date:  2002-04-05       Impact factor: 4.354

2.  Delineating origins of stereocontrol in asymmetric Pd-catalyzed alpha-hydroxylation of 1,3-ketoesters.

Authors:  Alexander M R Smith; Henry S Rzepa; Andrew J P White; Denis Billen; King Kuok Mimi Hii
Journal:  J Org Chem       Date:  2010-05-07       Impact factor: 4.354

3.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

4.  Ni(II)-catalyzed enantioselective Nazarov cyclizations.

Authors:  Irene Walz; Antonio Togni
Journal:  Chem Commun (Camb)       Date:  2008-07-17       Impact factor: 6.222

5.  Enantioselective 1,3-dipolar cycloaddition of C,N-cyclic azomethine imines to unsaturated nitriles catalyzed by NiII-Pigiphos.

Authors:  Sandra Milosevic; Antonio Togni
Journal:  J Org Chem       Date:  2013-09-16       Impact factor: 4.354

6.  Enantioselective addition of secondary phosphines to methacrylonitrile: catalysis and mechanism.

Authors:  Aaron D Sadow; Antonio Togni
Journal:  J Am Chem Soc       Date:  2005-12-07       Impact factor: 15.419

Review 7.  From a chiral switch to a ligand portfolio for asymmetric catalysis.

Authors:  Hans-Ulrich Blaser; Benoît Pugin; Felix Spindler; Marc Thommen
Journal:  Acc Chem Res       Date:  2007-08-24       Impact factor: 22.384

8.  Use of intensity quotients and differences in absolute structure refinement.

Authors:  Simon Parsons; Howard D Flack; Trixie Wagner
Journal:  Acta Crystallogr B Struct Sci Cryst Eng Mater       Date:  2013-05-17

9.  The Cambridge Structural Database.

Authors:  Colin R Groom; Ian J Bruno; Matthew P Lightfoot; Suzanna C Ward
Journal:  Acta Crystallogr B Struct Sci Cryst Eng Mater       Date:  2016-04-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.